Alendronate Sodium Monohydrate: A Comprehensive Guide for Patients with Diabetes and Bone Health Concerns

What is Alendronate Sodium Monohydrate?

Alendronate Sodium Monohydrate, also known by its brand name Alendronat Teva, is a medication primarily used to treat bone-related conditions. It belongs to a class of drugs called bisphosphonates1. The medication comes in the form of 70 mg tablets and is typically taken orally (by mouth).

Medical Conditions Treated

Alendronate is primarily used to treat and prevent conditions related to bone health, particularly in patients with diabetes. The main conditions it addresses are:

• Osteopenia: A condition where bone density is lower than normal but not low enough to be classified as osteoporosis.
• Osteoporosis: A more severe condition where bones become fragile and are at a higher risk of fracture.
• Diabetes-related bone issues: Both Type 1 and Type 2 diabetes can affect bone health, and Alendronate may be prescribed to manage these effects1.

How Alendronate Works

Alendronate works by slowing down the process of bone breakdown in your body. It helps to maintain or increase bone density, making bones stronger and less likely to break. In medical terms, it's known as an "antiresorptive" medication, meaning it prevents the loss of bone mass1.

Current Clinical Trial

A Phase 4 clinical trial is currently being conducted to further investigate the effects of Alendronate. The main objectives of this trial are:

1. To study how Alendronate affects bone markers (indicators of bone health) in patients with diabetes.
2. To examine how Alendronate impacts glycemic markers (indicators of blood sugar levels) in diabetic patients.
3. To compare these effects between Type 1 and Type 2 diabetes patients.
4. To evaluate different methods of assessing bone health in diabetic patients1.

Eligibility Criteria

The clinical trial has specific criteria for participants. Some key inclusion criteria are:

• Diagnosed with Type 1 or Type 2 diabetes
• Age 50 or older
• Stable diabetes treatment for the last six months
• HbA1c level (a measure of average blood sugar over 2-3 months) of 6.7% or higher in the last six months
• Body Mass Index (BMI) between 19 and 35
• Specific bone density measurements (DXA T-score between -3.5 and -0.5)1

There are also several exclusion criteria, such as very high HbA1c levels, pregnancy, certain medical conditions, and use of specific medications.

Dosage and Administration

In the clinical trial, Alendronate is being administered as follows:

• The medication used is Alendronat Teva 70 mg tablets.
• The maximum daily dose is 10 mg.
• The total treatment period is up to 24 months.
• The tablets are taken orally (by mouth).
• For the trial, the tablets are encapsulated in gelatin capsules by the Hospital Pharmacy1.

It's important to note that this dosage is specific to the clinical trial and may differ from standard prescriptions. Always follow your doctor's instructions when taking any medication.

Potential Side Effects and Precautions

While the clinical trial data doesn't provide specific information about side effects, it's important to be aware of potential risks and precautions when taking Alendronate:

• Patients with kidney disease (defined as eGFR < 50) are excluded from the trial, suggesting that kidney function is important when taking this medication.
• Those with abnormalities in the esophagus or factors that may delay esophageal transit time are also excluded, indicating potential risks related to the digestive system.
• Patients must be able to stand or sit for 30 consecutive minutes, which is likely related to how the medication should be taken to minimize side effects.
• Previous allergic reactions to the trial drug or to tetracycline (an antibiotic) are grounds for exclusion1.

Always discuss potential side effects and precautions with your healthcare provider before starting any new medication.